Literature DB >> 28115107

PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?

David F Heigener1, Martin Reck2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28115107     DOI： 10.1016/j.jtho.2016.12.013

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Immunotherapy strategy of EGFR mutant lung cancer.

Authors:  Shaorong Yu; Delin Liu; Bo Shen; Meiqi Shi; Jifeng Feng
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

Review 2.  [Lung cancer : What has been confirmed in therapy?]

Authors:  D F Heigener; M Reck
Journal:  Internist (Berl)       Date:  2017-12       Impact factor: 0.743

3.  The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.

Authors:  Mei Jiang; Aline F Fares; Daniel Shepshelovich; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Sanjay Shete; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; Sera Thomas; M Catherine Brown; Rayjean J Hung; Wei Xu; Geoffrey Liu
Journal:  Lung Cancer       Date:  2020-12-04       Impact factor: 5.705

4.  Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease.

Authors:  Pawan Kumar Singh; Rajender Kumar; Amanjit Bal; Nalini Gupta; Rakesh Kapoor; Kuruswamy Thurai Prasad; Navneet Singh
Journal:  JCO Glob Oncol       Date:  2020-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.